Adaptimmune Therapeutics Plc Cash Flow-to-Debt Ratio
Adaptimmune Therapeutics Plc cash flow-to-debt ratio. Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow-to-Debt Ratio of -0.17x as of June 2025, meaning its operating cash flow of $-34.78 Million could theoretically repay 0% of its total liabilities ($201.59 Million) in one year. Check Adaptimmune Therapeutics Plc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Adaptimmune Therapeutics Plc (2012–2024)
Cash flow-to-debt ratio of Adaptimmune Therapeutics Plc from 2012 to 2024. Historical debt coverage capacity for Adaptimmune Therapeutics Plc across 13 annual periods. Check ADAP cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Adaptimmune Therapeutics Plc Cash Flow-to-Debt Ratio by Year (2012–2024)
Adaptimmune Therapeutics Plc cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Adaptimmune Therapeutics Plc. For the full cash flow conversion analysis, see Adaptimmune Therapeutics Plc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-73.21 Million | $234.11 Million | ▲ +46.0% |
| 2023 | -0.58x | $-140.88 Million | $243.10 Million | ▼ -1.0% |
| 2022 | -0.57x | $-141.77 Million | $247.04 Million | ▼ -1509.9% |
| 2021 | 0.04x | $10.73 Million | $263.58 Million | ▲ +108.3% |
| 2020 | -0.49x | $-53.59 Million | $109.92 Million | ▲ +74.9% |
| 2019 | -1.94x | $-112.51 Million | $57.91 Million | ▲ +44.4% |
| 2018 | -3.50x | $-104.39 Million | $29.85 Million | ▼ -403.2% |
| 2017 | -0.69x | $-54.31 Million | $78.16 Million | ▲ +1.4% |
| 2016 | -0.70x | $-48.17 Million | $68.37 Million | ▲ +11.6% |
| 2015 | -0.80x | $-32.74 Million | $41.07 Million | ▼ 0.0% |
| 2014 | -0.80x | $-32.74 Million | $41.07 Million | ▼ -213.7% |
| 2013 | 0.70x | $37.23 Million | $53.11 Million | ▲ +135.8% |
| 2012 | -1.96x | $-7.77 Million | $3.97 Million | — |